source
- Merck licenses KRAS G12D inhibitor from Tao Hu for $400 million upfrontMerck has signed a licensing agreement for a KRAS G12D inhibitor, providing an upfront payment of $400 million. The deal follows a 2023 transaction in which the same entrepreneur, synthetic chemis…
- Adicet Bio reports early CAR-T therapy improves lupus symptoms, plans pivotal trial as shares fallAdicet Bio said its off-the-shelf CAR-T cell therapy showed signs of efficacy in a small early-stage trial involving patients with systemic lupus erythematosus. The study reported measurable impro…